Natural Product (NP) Details
General Information of the NP (ID: NP3076) | |||||
---|---|---|---|---|---|
Name |
Clavulanate
|
||||
Synonyms |
CLAVULANIC ACID; Clavulanate; 58001-44-8; Acido clavulanico; Acide clavulanique; Antibiotic MM 14151; acidum clavulanicum; Clavulansaeure; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; MM 14151; BRL 14151; BRL-14151; Clavulanate acid; CHEBI:48947; CLAVULANATE POTASSIUM; UNII-23521W1S24; (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; CHEMBL777; rx-10100; Sodium Clavulanate; Clavulansaeure [INN]; 23521W1S24; CLAVULANATE LITHIUM; Clavulinic Acid; Acide clavulanique [INN-French]; Acido clavulanico [INN-Spanish]; Acidum clavulanicum [INN-Latin]; Clavulox (TN); BRL-14151K; Clavulanic acid (INN); EINECS 261-069-2; 3008-B; BRN 0787059; Clavulanic acid [INN:BAN]; clavulonic acid; BRL14151; (Z)-(2R,5R)-3-(2-Hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; Epitope ID:117130; SCHEMBL6093; SCHEMBL34260; BSPBio_002430; DTXSID2022830; GTPL11128; ZINC3830569; BDBM50021959; AKOS016009164; DB00766; NCGC00188985-01; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2-alpha,3Z,5-alpha))-; SBI-0206779.P001; A12384; C06662; D07711; 49700-EP2275102A1; 49700-EP2295432A1; 49700-EP2308874A1; 49700-EP2311825A1; 001C448; Q415709; W-105420; Clavulanic acid, Antibiotic for Culture Media Use Only; (2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2beta-carboxylic acid; 1365254-41-6; 4-Oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,3-(2-hydroxyethylidene)-7-oxo-,(2R,3Z,5R)-
Click to Show/Hide
|
||||
Species Origin | Streptomyces clavuligerus ... | Click to Show/Hide | |||
Streptomyces clavuligerus | |||||
Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | Approved | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C8H9NO5
|
||||
PubChem CID | |||||
Canonical SMILES |
C1C2N(C1=O)C(C(=CCO)O2)C(=O)O
|
||||
InChI |
1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1
|
||||
InChIKey |
HZZVJAQRINQKSD-PBFISZAISA-N
|
||||
CAS Number |
CAS 58001-44-8
|
||||
ChEBI ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Amoxicillin | Bacterial infection | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
In-vivo Model | Clinical Trial | |||||
Experimental
Result(s) |
Amoxicillin/clavulanic acid is a useful therapeutic addition to the existing forms of treatment for amoxicillin-resistant respiratory tract infections. | |||||
Amoxicillin + Gentamicin | Click to Show/Hide the Molecular Data of This Drug | |||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Staphylococcus aureus | Microorganism model | Staphylococcus aureus | |||
Susceptible Saureus | Microorganism model | Susceptible Saureus | ||||
In-vivo Model | Forty-two female New Zealand white rabbits were used as animal model in this study. | |||||
Experimental
Result(s) |
1,8-cineole showed a synergistic effect in combination with both AMC and gentamicin, which offer possibilities for reducing antibiotic usage. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Staphylococcus beta-lactamase (Stap-coc blaZ) | Molecule Info | [5] |